Pfizer Doubles Down on Weight-Loss Market with $10B Metsera Acquisition

Pfizer acquires obesity-drug developer Metsera for $10B, entering a booming weight-loss market. CEO Albert Bourla vows to be a "formidable competitor" with a first weight-loss treatment expected by 2028. The market is estimated at $150-$200B, with Pfizer aiming to capture a share through its own pipeline and direct-to-consumer platform.